Sarepta Therapeutics SRPT NASDAQ · Healthcare · United States
$14.53 -1.62% -$0.24
Summary
42 / 100 · Bulios Score
What speaks for it
- Revenue grew by 33% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
What to watch
- Analysts expect revenue to fall by 15% this fiscal year.
- Out of every 100 USD of revenue, only 0.8 USD is left as net profit.
- Repaying its net debt would take 3.7 years of operating profit.
- It missed profit estimates 4 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBy our assumptions the business is worth more than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 105.6 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 32% a year over 5 years. Over the last 3 years it grew by 33% a year. For the next fiscal year analysts expect revenue to fall by 15%.
Growth in detailDoes it make money?
PoorlyWhere 100 USD of revenue goes
- Cost of sales 44 USD
- Research and development 33 USD
- Sales and administration 25 USD
- Taxes and other -3.3 USD
- Net profit 0.8 USD
Net profit, industry median (Biotechnology) -10 USD
Out of every 100 USD of revenue, 0.8 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 31
- Hold 18
- Sell 6
Today's price within the analysts' price targets
The average target of $21.6 is 49% above today's price. 56% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
The company reports no revenue by product.
By region
- UNITED STATES 84%
- Non-US 16%
UNITED STATES brings in 84% of revenue. Non-US grew fastest, by 20% a year.
Segments in detail